Common Drugs for Prostate Cancer: A Complete Guide to Hormone Therapy, Targeted Therapy & Chemotherapy
Common drugs for prostate cancer include androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs),…
News
Plozasiran Now Available in China: A Once-Every-3-Month siRNA Therapy for Familial Chylomicronemia Syndrome (FCS)
Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted…
Ciprocopan Approved in China as the World’s First Once-Daily Oral CFB Inhibitor for PNH
Ciprocopan approved in China as the world’s first once-daily oral Complement Factor B (CFB) inhibitor,…
Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy
Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R)…
Gene Therapy for Beta Thalassemia: Can CRISPR and Gene Addition Achieve Transfusion Independence?
For patients living with transfusion-dependent beta thalassemia (TDT), lifelong blood transfusions have long been the…
The First Approved ADC for Esophageal Squamous Cell Carcinoma (ESCC): How Izalontamab Brengitecan Is Transforming Treatment
Izalontamab Brengitecan is the first approved ADC for esophageal squamous cell carcinoma (ESCC) worldwide. It…
Complete Lung Cancer Drugs List (2026 Update)
Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer…
Adamgammadex Sodium Approved by NMPA: The World’s Second and China’s First Homegrown Targeted Neuromuscular Block Reversal Agent
On July 1, China’s National Medical Products Administration (NMPA) approved Adamgammadex Sodium Injection for marketing.…
ALK Inhibitors for Lung Cancer: Generational Evolution and Impact on Clinical Practice
Before the advent of targeted therapy, ALK-positive advanced non-small cell lung cancer (NSCLC) typically progressed…
Octahydroaminoacridine Succinate Approved in China for Alzheimer’s Disease, Marking Progress in Innovative Drug Development
On June 25, 2026, the National Medical Products Administration (NMPA) announced Octahydroaminoacridine Succinate approved in…